{"nctId":"NCT00605345","briefTitle":"A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.","startDateStruct":{"date":"2007-12"},"conditions":["Anemia"],"count":71,"armGroups":[{"label":"CERA Treatment Once Monthly","type":"EXPERIMENTAL","interventionNames":["Drug: methoxy polyethylene glycol-epoetin beta [Mircera]"]},{"label":"Darbepoetin Alfa Once Biweekly","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Darbepoetin alfa"]}],"interventions":[{"name":"Darbepoetin alfa","otherNames":[]},{"name":"methoxy polyethylene glycol-epoetin beta [Mircera]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\> or = 18 years of age;\n* kidney transplant recipients with stage 3 or stage 4 chronic kidney disease;\n* functioning graft of \\> 6 months and \\< 10 years after kidney transplantation, with no signs of acute rejection;\n* stable maintenance subcutaneous darbepoetin alfa therapy every 2 weeks.\n\nExclusion Criteria:\n\n* transfusion of red blood cells during previous 2 months;\n* poorly controlled hypertension;\n* significant acute or chronic bleeding;\n* need for dialysis therapy expected in next 6 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants Maintaining Average Haemoglobin (Hb) Concentration During the Efficacy Evaluation Period (EEP) Within the Target Range","description":"Key outcomes will be assessed during the first 12 weeks following the 16 weeks dose titration period, i.e. during the Efficacy Evaluation Period (EEP). Assessments performed every four weeks, beginning at week 16 up to week 28. The reference haemoglobin is defined as the mean of the two assessments recorded during the SVP (weeks -4 and -2). For the purposes of efficacy assessment the target haemoglobin concentration range will be defined as Â± 1 g/dL of the reference haemoglobin concentration AND within the range 10 - 12 g/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.29","spread":null},{"groupId":"OG001","value":"57.14","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Hb Concentration From Baseline to Efficacy Evaluation Period (EEP)","description":"Reference haemoglobin at baseline is defined as the mean of the two assessments recorded at weeks -4 and -2. Additional assessments were then performed every 4 weeks at week 0 through week 28. Mean change was calculated as value at 28 weeks minus baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.85"},{"groupId":"OG001","value":"0.05","spread":"1.06"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Maintaining Hb Concentration in 10-12 g/dL Range Throughout the Efficacy Evaluation Period (EEP)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.7","spread":null},{"groupId":"OG001","value":"64.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Time Spent in 10-12g/dL Range During the Efficacy Evaluation Period (EEP)","description":"Efficacy Evaluation Period was the 12 weeks following 16 weeks of treatment in the Dose Titration Period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":"23.98"},{"groupId":"OG001","value":"50.5","spread":"27.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Needing Dose Adjustments","description":"Assessment of the Dose Titration Period of 16 weeks of treatment and following 12 weeks, known as the Efficacy Evaluation Period (EEP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.9","spread":null},{"groupId":"OG001","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"20.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of RBC Transfusions","description":"Assessment of the Dose Titration Period of 16 weeks of treatment and following 12 weeks, known as the Efficacy Evaluation Period (EEP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":46},"commonTop":["Hypertension","Diarrhoea","Oedema Peripheral","Nasopharyngitis","Upper Respiratory Tract Infection"]}}}